JP2009504654A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504654A5
JP2009504654A5 JP2008526124A JP2008526124A JP2009504654A5 JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5 JP 2008526124 A JP2008526124 A JP 2008526124A JP 2008526124 A JP2008526124 A JP 2008526124A JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5
Authority
JP
Japan
Prior art keywords
vaccine
yellow fever
chimeric flavivirus
fever virus
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008526124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504654A (ja
JP5227172B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/030846 external-priority patent/WO2007021672A2/en
Publication of JP2009504654A publication Critical patent/JP2009504654A/ja
Publication of JP2009504654A5 publication Critical patent/JP2009504654A5/ja
Application granted granted Critical
Publication of JP5227172B2 publication Critical patent/JP5227172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008526124A 2005-08-10 2006-08-09 デングウイルス感染に対するワクチン接種 Expired - Fee Related JP5227172B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70703805P 2005-08-10 2005-08-10
US60/707,038 2005-08-10
US71944805P 2005-09-22 2005-09-22
US60/719,448 2005-09-22
PCT/US2006/030846 WO2007021672A2 (en) 2005-08-10 2006-08-09 Vaccination against dengue virus infection

Publications (3)

Publication Number Publication Date
JP2009504654A JP2009504654A (ja) 2009-02-05
JP2009504654A5 true JP2009504654A5 (https=) 2010-08-19
JP5227172B2 JP5227172B2 (ja) 2013-07-03

Family

ID=37758084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526124A Expired - Fee Related JP5227172B2 (ja) 2005-08-10 2006-08-09 デングウイルス感染に対するワクチン接種

Country Status (12)

Country Link
US (1) US20080193477A1 (https=)
EP (1) EP1924280A4 (https=)
JP (1) JP5227172B2 (https=)
AR (1) AR055603A1 (https=)
AU (1) AU2006280144B2 (https=)
BR (1) BRPI0614265A2 (https=)
CA (1) CA2618783A1 (https=)
IL (1) IL189329A (https=)
MY (1) MY151051A (https=)
NO (1) NO20081127L (https=)
TW (1) TW200740458A (https=)
WO (1) WO2007021672A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
KR20160119806A (ko) * 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
DK3197487T3 (da) 2014-09-26 2022-09-05 Seqirus Uk Ltd Vaccination af immunsvækkede individer
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
WO2018183429A1 (en) 2017-03-30 2018-10-04 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
US20250342705A1 (en) 2022-05-04 2025-11-06 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US6966281B1 (en) * 2004-05-05 2005-11-22 Hale James R Internal combustion device and methods of use
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Similar Documents

Publication Publication Date Title
JP2009504654A5 (https=)
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
Khetarpal et al. Dengue fever: causes, complications, and vaccine strategies
JP6830118B2 (ja) ワクチン組成物
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
JP2013542224A5 (https=)
ES2337893T3 (es) Vacuna del virus del nilo occidental.
JP2008529558A5 (https=)
JP2008530245A5 (https=)
JP6943908B2 (ja) 迅速かつ持続的な免疫学的治療法
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
AU2017297608A1 (en) Compositions and methods for flavivirus vaccination
Zingaretti et al. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
AU2022205163B2 (en) Hepatitis B immunisation regimen and compositions
JP2023518340A5 (https=)
Takei et al. Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice
JP2010506926A5 (https=)
Chen et al. Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses
Valiakos et al. West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence
CN116348101A (zh) 嵌合腺病毒载体
Kieny et al. Research and development of new vaccines against infectious diseases
ES2644801T3 (es) Antígenos de vacuna quimérica contra el virus de la hepatitis c
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
BR112021004049A2 (pt) vacinas vivas atenuadas lançadas por plasmídeo de dna para vírus de rna de fita simples de sentido positivo
Sanicas et al. A review of COVID-19 vaccines in development: 6 months into the pandemic